Few seroconversions were observed1,2

Seroconversions from baseline to ≥96 weeks

  • Of the seroconversions observed at ≥96 weeks, 1 participant in the DESCOVY arm and 4 participants in the FTC/TDF arm had suspected baseline infections
  • At primary analysis, when 100% of participants reached Week 48 and ≥50% reached Week 96, 7 participants using DESCOVY seroconverted vs 15 participants using FTC/TDF

Adherence testing at primary analysis

  • In a case-control substudy, dried blood spot testing measured intracellular TFV-DP levels in red blood cells and estimated number of daily doses at HIV diagnosis
  • Median intracellular drug levels were substantially lower in participants infected with HIV-1 at the time of diagnosis vs uninfected, matched control participants. Values for 1 participant in the DESCOVY arm are not available

Seroconversions from baseline to ≥144 weeks3

  • In addition to the seroconversions at ≥96 weeks, 3 additional seroconversions occurred in the DESCOVY arm (n=2070)

Efficacy is strongly correlated with adherence.

FTC/TDF=emtricitabine/tenofovir disoproxil fumarate; PY=person-years; TFV-DP=tenofovir diphosphate.